ScaleWiki
Explore our comprehensive collection of scientific resources, from application notes and case studies to videos and webinars.
Share
Filter By
Cell Types
Filter by G- Rex Models
Filter by Year
Publications
TCR T Cells
G-Rex500M
T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial [High Res Image]
High-resolution graphical abstract of the KRAS G12V TCR-T trial. It traces PBMC isolation, lentiviral TCR transduction, rapid expansion in a G-Rex 500M vessel, and infusion after lymphodepletion. Outcomes shown: low-grade CRS, one complete response, and anti-TCR antibody driving rejection.
Publications
CAR T Cells, CD34 Cells, NKT Cells
G-Rex6M – 10cm²
Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells
Allogeneic MSLN CAR-NKT cells were generated from cord blood CD34+ HSPCs. They outperformed conventional CAR-T cells in ovarian cancer, homed to tumors, modulated the microenvironment, minimized cytokine release syndrome and GvHD, and resisted allorejection. Expansion used G-Rex 6M well plates.
Publications
TCR T Cells
G-Rex500M
T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial
Single-arm phase 1/2 trial NCT04146298 treated five recurrent pancreatic cancer patients with autologous T cells engineered with an HLA-A*11:01-restricted KRAS G12V TCR; three had repeat infusions. Products were rapidly expanded in G-Rex 500 flasks and rested in G-Rex 24-well plates (Wilson Wolf).
Publications
CAR T Cells
G-Rex6M – 10cm²
DSG2-Directed CAR-T Cells Safely and Universally Eliminate Solid Tumors
Desmoglein 2 is universally overexpressed on transformed epithelial cells but junction-restricted in normal tissue. Anti-DSG2 CAR-T cells lysed varied solid tumor lines and eliminated colon, pancreatic, lung, prostate, breast and liver tumors in vivo. Cells expanded 10 days in a G-Rex 6M system.
Publications
CAR T Cells, T-Cells
Engineering “physically optimized” T cells for increased sampling of complex tumor microenvironments
Constitutively active RhoA raises cortical contractility, activation, migration and tumor sampling in T cells while lowering exhaustion markers. CAR T cells engage carcinoma cells faster and improve pancreatic tumor control in vivo. Sorted T cells were expanded 3 extra days in 24-well G-Rex.
Publications
CAR T Cells
Lentiviral-mediated panErbB CAR-T cell therapy against head and neck squamous cell carcinomas for patients with Fanconi anemia
PanErbB CAR-T cells were made by lentiviral transduction of Fanconi anemia and healthy donor T cells and killed HNSCC models, offering an alternative to toxic radio-chemotherapy. Cells were expanded in G-Rex GMP-scalable devices (Wilson Wolf) under hypoxia, with viability above 70%.
Publications
CAR T Cells
Preclinical comparison of non-signaling domain in CD19 CAR T cell with interleukin-7 receptor alpha signaling domain
Three non-signaling domain designs were tested in a CD19 CAR with 4-1BB and IL-7R alpha. IgG2/CD28 lowered expression and function, CD8/CD8 gave the highest density, and IgG2.CH3/CD28 raised cytokines and persistence. CAR T cells were cultured in G-Rex plates (Wilson Wolf).
Publications
Treg Cells
G-Rex10M
Preclinical efficacy and safety assessment of engineered regulatory T cells for treatment of IPEX and other autoimmune disorders
HDR editing integrates a functional FOXP3 cDNA into CD4+ T cells to create engineered Tregs for IPEX. The study reports targeting efficiency, enrichment, off-target analysis and in vivo suppression. Enriched EngTregs were expanded 7 days in G-Rex flasks with CD3/CD28 beads, IL-2 and rapamycin.
